Study design and rationale for biomedical shirt-based electrocardiography monitoring in relevant clinical situations: ECG-shirt study by Balsam, Paweł et al.
Address for correspondence: Piotr Lodziński, MD, PhD, First Chair and Department of Cardiology, Medical University of 
Warsaw, Public Central Teaching Hospital in Warsaw, ul. Banacha 1a, 02–097 Warszawa, Poland, tel: +48 22 5992958,  
fax: +48 22 5991957, e-mail: piotr.lodzinski@me.com
Received: 05.07.2017 Accepted: 07.08.2017
CLINICAL CARDIOLOGY
Cardiology Journal 
2018, Vol. 25, No. 1, 52–59
DOI: 10.5603/CJ.a2017.0102 
Copyright © 2018 Via Medica
ISSN 1897–5593
52 www.cardiologyjournal.org
ORIGINAL ARTICLE
Study design and rationale for biomedical  
shirt-based electrocardiography monitoring  
in relevant clinical situations: ECG-shirt study
Paweł Balsam1, Piotr Lodziński1, Agata Tymińska1, Krzysztof Ozierański1,  
Łukasz Januszkiewicz1, Renata Główczyńska1, Katarzyna Wesołowska2, Michał Peller1, 
Radosław Pietrzak3, Tomasz Książczyk3, Sonia Borodzicz1, Łukasz Kołtowski1,  
Mariusz Borkowski4, Bożena Werner3, Grzegorz Opolski¹, Marcin Grabowski1
11st Chair and Department of Cardiology, Medical University of Warsaw,  
Public Central Teaching Hospital in Warsaw, Poland 
2Department of Clinical Nursing, Medical University of Warsaw,  
Public Central Teaching Hospital in Warsaw, Poland 
3Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, Poland 
4Orlik Medical Practice, Warsaw, Poland
Abstract 
Background: Today, the main challenge for researchers is to develop new technologies which may 
help to improve the diagnoses of cardiovascular disease (CVD), thereby reducing healthcare costs and 
improving the quality of life for patients. This study aims to show the utility of biomedical shirt-based 
electrocardiography (ECG) monitoring of patients with CVD in different clinical situations using the 
Nuubo® ECG (nECG) system.
Methods: An investigator-initiated, multicenter, prospective observational study was carried out in  
a cardiology (adult and pediatric) and cardiac rehabilitation wards. ECG monitoring was used with 
the biomedical shirt in the following four independent groups of patients: 1) 30 patients after pulmonary 
vein isolation (PVI), 2) 30 cardiac resynchronization therapy (CRT) recipients, 3) 120 patients during 
cardiac rehabilitation after myocardial infarction, and 4) 40 pediatric patients with supraventricular 
tachycardia (SVT) before electrophysiology study. Approval for all study groups was obtained from the 
institutional review board. The biomedical shirt captures the electrocardiographic signal via textile 
electrodes integrated into a garment. The software allows the visualization and analysis of data such 
as ECG, heart rate, arrhythmia detecting algorithm and relative position of the body is captured by an 
electronic device. 
Discussion: The major advantages of the nECG system are continuous ECG monitoring during daily 
activities, high quality of ECG recordings, as well as assurance of a proper adherence due to adequate 
comfort while wearing the shirt. There are only a few studies that have examined wearable systems, 
especially in  pediatric populations. 
Trial registration: This study is registered in ClinicalTrials.gov: Identifier NCT03068169. (Cardiol J  
2018; 25, 1: 52–59)
Key words: remote electrocardiography, atrial fibrillation, cardiac rehabilitation, cardiac 
resynchronization therapy, electrophysiological study, myocardial infarction, mobile 
health, pulmonary veins isolation, supraventricular tachycardia, telehealth, telemedicine
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Introduction
Cardiovascular diseases (CVD) are associated 
with high healthcare costs as well as being a lead-
ing cause of mortality and hospitalization. This is 
an important medical, economic and social problem. 
Researchers today are puzzled on how to develop new 
monitoring technologies which improve diagnosis of 
CVD, reduce healthcare costs and improve the quality 
of life for patients. Over recent years, non-invasive 
wearable electronics offer new opportunities for the 
diagnosis and management of patients with CVD 
[1–3]. Biophysical signals may now be easily recorded 
and transmitted using wired or wireless communica-
tion and analysed anywhere, at any time.
Several reports have been published, in which 
wearable devices achieved very positive results 
with high diagnostic accuracy [3–6]. It was dem-
onstrated that a garment-inserted electrocardi-
ography (ECG) system can obtain similar results 
to those achieved with the conventional treadmill 
system during exercise testing,which may also in-
clude obtaining echocardiographic images [3]. Most 
importantly, the wearable system was invented to 
allow remote ECG monitoring during everyday 
activities. It was found useful in patients with coro-
nary artery disease undergoing in-home cardiac 
rehabilitation [6]. Asimilar system (consisting of 
accelerometer and ECG) was also used to monitor 
heart rate and activities of rescuers (fire fighters 
and Civil Protection rescuers) during emergency 
interventions [4]. Kwon et al. [5] investigated 
a brassiere-based ECG monitoring system (Cardio-
Guard), which showed a high degree of reliability 
for daily continuous ECG monitoring in women. 
What is important, all wearable ECG systems 
presented to be comfortable during tests. This 
ensures an adequate level of adherence, mainly due 
to their non-invasive nature and non-interference 
with normal daily life activities [3–6].
The aim of this study is to show the utility of 
biomedical shirt-based ECG monitoring of patients 
with CVD in different clinical situations using the 
Nuubo ECG (nECG) system.
Methods
ECG platform
The system consists of biomedical nECG shirt, 
an electronic device and ECG software (Fig. 1). The 
biomedical shirt captures the electrocardiographic 
signal via the textile electrodes integrated into 
the garment. The biomedical shirt enables non-
invasive registration of a medical-quality 3-lead 
ECG signal through adherence of textile electrodes 
to the skin. The biomedical shirt-ECG monitoring 
is based on BlendFix® sensor electrode technology 
that is capable of being used in real-time and for 
continuous recording. In the front of the shirt an 
electronic device with a memory card is attached 
that stores the ECG signal (as well as data form 
accelerometer and GPS). The battery for the device 
lasts for 36 h. The device transmits information 
via Bluetooth to a computer for visualization and 
analysis of ECG, heart rate, arrhythmia detecting 
algorithm and relative position of the body cap-
tured by the electronic device. The Nuubo shirt 
is washable allowing greater comfort for the user. 
The platform is Conformité Européenne certified 
as a medical device for use in the European Union. 
It has been tested in patients who have undergone 
an exercise echocardiography test [3] and cardiac 
rehabilitation [6].
Study design
An investigator-initiated, multicenter, pro-
spective observational study was carried out in 
a cardiology (adult and paediatric) and cardiac reha-
bilitation wards of two tertiary university hospitals. 
ECG was monitored using the biomedical shirt in 
the following four independent groups of patients: 
1) 30 patients after pulmonary veins isolation 
(PVI); 2) 30 cardiac resynchronization therapy 
(CRT) recipients; 3) 120 patients during cardiac 
rehabilitation after myocardial infarction (MI), 
and 4) 40 pediatric patients with supraventricular 
tachycardia (SVT) before electrophysiology study 
(Fig. 2). Approval for all study groups was obtained 
from institutional review board. The study protocol 
conforms to the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013 
statement (Table 1A–D) [7]. See additional file 
containing SPIRIT Checklist. The study received 
ClinicalTrials.gov number, NCT03068169.
Rationale for biomedical shirt-based ECG 
monitoring of the blanking period  
and long-term effectiveness of the PVI
Pulmonary veins isolation is a well-known 
method for atrial fibrillation treatment [8]. How-
ever, its efficiency is estimated at approximately 
70% and depends on many factors [8]. Blanking 
period is referred to as an immediate 3-month 
period post PVI in which early recurrences of 
atrial tachyarrhythmias (ERAT) are not considered 
clinically significant [9, 10]. Not all ERAT lead to 
later recurrences, and do not necessarily represent 
treatment failure [10, 11]. However, it is not known 
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whether ERAT burden in the blanking period is 
related to the long-term efficiency of the PVI. 
Rationale for biomedical shirt-based ECG 
monitoring of the BiV% and physical  
activity in CRT recipients
Cardiac resynchronization therapy is an estab-
lished therapeutic strategy for patients with symp-
tomatic heart failure and wide QRS complex [12]. 
However, approximately 1 in 3 CRT recipients do 
not respond to the therapy and do not derive benefit 
from CRT [13]. The CRT non-response problem is 
multifactorial. A proper qualification, impeccable 
procedure and appropriate programming are keys 
to therapy improvement [14]. Many studies have 
clearly shown that CRT beneficial effects can be 
achieved when biventricular pacing (BiV%) is as 
close to 100% as possible [14]. Therefore, devices 
must present the correct BiV%. Unfortunately, 
because of frequent improper fusion and pseudo-
fusion beats identification, BiV% measured by the 
device might be overestimated. Data on the mis-
match between the BiV% measured by the device 
and true BiV% is scarce [15]. 
Rationale for biomedical shirt-based ECG 
monitoring during cardiac rehabilitation  
after myocardial infarction
Patients after acute coronary syndromes are 
exposed to an increased risk of recurrent MI, and 
therefore they should be referred for secondary 
prevention programs, which include cardiac reha-
bilitation. There is strong scientific evidence show-
ing reduction of mortality among MI patients who 
Figure 1. The wireless remote electrocardiogram platform consists of biomedical shirt, electronic device and software 
package.
Figure 2. Study groups; AF — atrial fibrillation; CRT — cardiac resynchronization therapy; ECG — electrocardiography; 
MI — myocardial infarction; nECG — Nuubo electrocardiogram; PVI — pulmonary vein isolation; SVT — supra­
ventricular tachycardia
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Table 1. Recommendations for Interventional Trials (SPIRIT) 2013 statement.
A. Pediatric patients with supraventricular tachycardia (SVT).
STUDY PERIOD
Enrolment Allocation Monitoring Hospitalization Close-out
TIME POINT –1 week 0 1st month 2nd month 3rd month
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
ASSESSMENTS:
Gathering medical and  
demographic data
X
nECG shirt based monitoring X
Electrophysiology study (EPS) X
Assessment of the SVT diagnosis  
basing on the nECG shirt and EPS
X
Preparation of conclusions of the study X
B. Patients during cardiac rehabilitation after myocardial infarction.
STUDY PERIOD
Enrolment Allocation Monitoring Assessments Close-out
TIME POINT –1 week 0 1st month After 1st month 3rd month
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
Randomization X
ASSESSMENTS:
Gathering medical and  
demographic data
X
nECG shirt based monitoring X
Performance of the standardized  
questionnaire
X X
Assessment of the study outcomes X
Preparation of conclusions of the study X
C. Cardiac resynchronization therapy recipients.
STUDY PERIOD
Enrolment Allocation Monitoring Assessments Close-out
TIME POINT –1 week 0 3 months After 3rd month 4th month
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
ASSESSMENTS:
Gathering medical and  
demographic data
X
nECG shirt based monitoring X
Assessment of the study outcomes X
Preparation of conclusions of the study X
Æ
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Table 1 (cont.). Recommendations for Interventional Trials (SPIRIT) 2013 statement.
D. Patients after pulmonary vein isolation.
STUDY PERIOD
Enrolment Allocation Monitoring Assess-
ments
Close-
out
TIME POINT –1 week 0 1st  
month
7th  
month
13th 
month
After 13th 
months
15th 
month
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
ASSESSMENTS:
Gathering medical and demographic data X
Pulmonary veins isolation X
nECG shirt based monitoring X X X
Assessment of the study outcomes X
Preparation of conclusions of the study X
Table 2. Inclusion and exclusion criteria.
Patients after PVI  CRT recipients  Patients during  
cardiac rehabilitation 
after MI 
Pediatric patients  
with SVT 
Inclusion criteria
Participants  AF patients after  
recent PVI
CRT recipients Patients within  
3 months after MI, after 
completing early post­
infarction ambulatory 
cardiac rehabilitation
Patients with  
diagnosed SVT  
qualified to  
electrophysiology  
study
Age 18–70 years old ≥ 18 years old 18–80 years old 5–18 years
Exclusion criteria
Common criteria Chest size which made it impossible to wear an nECG shirt
Contraindications to wear biomedical shirt (structural disease of the chest, skin diseases,  
allergy for materials used in the ECG shirts)
Chronic inflammatory disease, severe chronic kidney disease
Active cancer, and a period of 5 years from the end of treatment
Specific criteria Body mass index  
≥ 35 kg/m2
Use of antiarrhythmic 
agents after PVI
Persistent AF
Previous PVI
Dysfunction of the 
lower limbs or other 
walking impairments
Unstable angina  
pectoris
Life­threatening  
arrhythmias
Decompensated  
congestive heart failure
Uncontrolled  
hypertension
Other contraindications 
to physical activity
AF — atrial fibrillation; CRT — cardiac resynchronization therapy; ECG — electrocardiography; MI — myocardial infarction; nECG — Nuubo 
electrocardiogram; PVI — pulmonary vein isolation; SVT — supraventricular tachycardia
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completed a comprehensive cardiac rehabilitation 
track involving exercise training, diet, risk factor 
modification, education and psychological support 
[16, 17]. Implementation of secondary prevention 
units in health care facilities is a key element in 
promoting the habits of regular physical activity 
among patients. Unfortunately, for many patients 
the access to these activities remains limited. In 
daily practice, a cardiac rehabilitation program is 
divided into three stages: 1) an introductory phase 
conducted in hospital; 2) an early rehabilitation 
phase run in an ambulatory or home environment; 
and 3) a late phase of ambulatory rehabilitation. It is 
assumed that the last phase of rehabilitation should 
last until the end of a patient’s life, therefore, it is 
very important to promote physical activity and 
monitor its intensity in everyday life. This can 
be achieved using different motivation tools, like 
pedometers or nECG shirts in which patients are 
comfortable and feel safe [18–20]. 
Rationale for biomedical shirt-based ECG 
monitoring to differentiate AVNRT from 
AVRT in pediatric patients
Supraventricular tachycardia is one of the 
most common arrhythmia in the pediatric popula-
tion [21]. There are two main mechanisms of SVT 
in pediatric patients, including atrioventricular 
reentry tachycardia (AVRT) and atrioventricular 
nodal reentry tachycardia (AVNRT). AVRT results 
from the presence of accessory pathways connect-
ing the tissues of the atrium and ventricle. This 
enables conduction in both directions (preexcited 
pathways) or retrograde conduction (concealed 
pathways). In the AVNRT, two conducting path-
ways forming the reentry circuit are located within 
the atrioventricular node [21]. 
Analysis of a 12-lead ECG is required to 
determine the treatment strategy and enable as-
sessment of the SVT mechanism [22]. However, 
it has been demonstrated, that evaluations of ECG 
obtained from Holter monitors and event record-
ers correctly determines the mechanism of SVT 
only in 45% of recordings [22]. Ferdman et al. 
[21] published the results of the study evaluating 
usefulness of the AliveCor smartphone application 
in distinguishing between AVRT and AVNRT in 
pediatric populations. The authors presented that 
a single-lead ECG obtained with a smartphone 
monitor can successfully record SVT in pediatric 
patients, it can also predict the SVT mechanism 
similar topreviously published reports of Holter 
monitors [21]. The recently published JUNIOR 
SVT SCORE showed a good ability to distinguish 
orthodromic AVRT from AVNRT, though further 
validation is needed [23].
Ethics approval and consent to participate
The study protocol and written consent form 
were approved by the Research Ethics Board of the 
Medical University of Warsaw. Any modifications 
of the protocol that might impact patient safety, 
confidentiality, or other significant conduct of the 
study were reviewed by the Research Ethics Board 
before implementation.
Study objectives
Patients after PVI. The purpose of this 
sub-study is to examine the rationale for the use 
of monitoring during a blanking period and to de-
termine whether the ERAT burden influences on 
long-term effectiveness of PVI. The study might 
demonstrate which patients with ERAT remain at 
risk of long-term recurrence of atrial fibrillation.
CRT recipients. The purpose of this sub-
study is to examine the extended monitoring in 
fusion and pseudo-fusion beats detection in CRT 
recipients to assess the true BiV%. The secondary 
aim is to assess the influence of CRT implantation 
on the amount of physical activity as measured by 
the nECG shirt.
Patients during cardiac rehabilitation 
after MI. The purpose of this sub-study is to as-
sess the impact of the use of a pedometer combined 
with nECG as motivation tools for increasing the 
level of daily physical activity and its intensity.
Pediatric patients with SVT. The purpose 
of this sub-study was to create an algorithm based 
on nECG monitoring to differentiate between 
AVRT and AVNRT in pediatric patients suffering 
from SVT.
Study populations and overall  
study description
The study consisted of four independent 
patient groups. Patients met all inclusion criteria 
and no exclusion criteria, as shown in Table 2, 
were enrolled in the study. All participants signed 
informed written consent, which was obtained by 
a physician. In the case of children, a consent form 
of their legal guardians was required. 
Patients after PVI. This arm of the study 
prospectively enrolled a cohort of 30 patients with 
paroxysmal AF treated with PVI. At hospital dis-
charge, patients after PVI received the biomedical 
shirt. Patients wore the shirt for 1-month (taken 
off only for bathing) after PVI, thereafter for two 
1-month periods, also after 6 and 12 months. 
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CRT recipients. This cohort consisted of 
30 patients scheduled for CRT implantation. Patients 
received the nECG system  1 month prior to CRT 
implantation. Patients wore the biomedical shirt for 
1 month before implantation to measure ECG and 
activity and then for 1-month after  CRT implanta-
tion. CRT response was assessed in the echocar-
diographic study performed 6 months subsequent 
to CRT implantation. An echocardiographic re-
sponses were defined as percent reduction in left 
ventricular end-diastolic volume between enrol-
ment and 6-month follow-up. The secondary aim 
was to assess the influence of CRT implantation on 
physical activity. The device algorithms measured 
physical activity. 
Patients during cardiac rehabilitation 
after MI. This arm of the study prospectively 
enrolled 120 patients within 3 months after MI, 
after completing early post-infarction ambulatory 
cardiac rehabilitation. The study was randomized 
(1:1 randomization) with a control group (60 pa-
tients) and a motivated group (60 patients).
Pediatric patients with SVT. This arm of the 
study prospectively enrolled a cohort consisting of 
40 patients, between 5 and 18 years old diagnosed 
with SVT and who are qualified for electrophysio-
logy study. Before performing electrophysiolo-
gy study, patients underwent continuous ECG 
monitoring using a biomedical shirt. Patients wore 
the nECG shirt for 1 month or until the first SVT 
registration. 
Study endpoints
Patients after PVI. The primary endpoint of 
the study was the atrial fibrillation burden during 
1-month ECG monitoring after PVI. The second-
ary endpoint was the influence of ERAT burden in 
the blanking period on PVI efficacy and therefore 
rationale for the use of a blanking period. 
CRT recipients. The primary endpoint of 
this sub-study was true BiV% observed within 
a 3-month period. Secondary outcomes described 
the influence of true BiV% on the CRT response 
and influence of CRT implantation on physical 
activity. 
Patients during cardiac rehabilitation 
after MI. The primary endpoint of this arm of 
the study was  average daily number of steps after 
a 1-month period of using pedometer combined 
with nECG. Secondary outcome was  motivational 
value to increasing physical activity assessed by 
standardized questionnaire taken before and after 
a 1-month period of intervention.
Pediatric patients with SVT. Differentia-
tion of AVNRT and AVRT using nECG monitoring. 
Results of  analysis was confronted with diagnosis 
based on electrophysiology study.
Power analysis
Because of the observational design of the 
study, there was an inability to calculate the exact 
sample size. However, the number of patients in 
each arm of the study appeared to be sufficient 
for checking the safety and efficacy of the method. 
Statistical analysis
Distribution for variables was assessed with 
the Shapiro-Wilk test. Normally and non-normally 
distributed continuous variables were presented as 
median and mean values, respectively. Categorical 
variables were presented as percentages. Statisti-
cal analysis was calculated with SAS® software, 
version 9.4.
Discussion 
A growing number of wearable or implantable 
technologies with sensors and therapy delivery 
devices is available. Recent advances in health 
monitoring devices enable recording of physiologi-
cal signals including ECG and physical activity dur-
ing daily life. Implementation of remote monitoring 
devices into healthcare system provides a unique 
opportunity for the patients to receive medical 
advice without presenting to a hospital or ambula-
tory care units. 
The major advantages of the nECG system 
include: continuous ECG monitoring during daily 
activities, high quality of ECG recordings, as well 
as assurance of a proper adherence due to adequate 
comfort of wearing the shirt. However, therehave 
been only a few studies evaluating such wearable 
systems. The wearable ECG monitoring adds sig-
nificant value to everyday clinical practice. In this 
study using the nECG we will investigate several 
important clinical problems, as was described in 
the protocol. 
Limitations of the study
The wearable ECG system has also some 
limitations derived from short battery life, de-
pendence from the user adherence and presence 
of artefacts during recordings. Especially, imple-
menting the nECG monitoring in children popula-
tion may provide some challenges. Moreover, the 
detection of asymptomatic atrial fibrillation with 
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new technologies, such as wearable shirts, has 
not yet been formally evaluated as an arrhythmia 
detection method [8].
Trial status: Patient recruitment has not yet started.
Funding: NUUBO provided without payment, the 
biomedical nECG shirts to carry out this study. 
NUUBO has no influence on the study design, data 
collection nor interpretation of data.
Conflict of interest: None declared
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